Abbott gains FDA approval for TactiCath AFib ablation catheter
Abbott on Jan. 21 announced the FDA approval of one of its atrial fibrillation (AFib) ablation catheters, the TactiCath Contact Force Ablation Catheter.
The sensor-enabled catheter “delivers more precise images of the heart overlaid with real-time electrical activity information,” according to the company’s announcement. It can be used in conjunction with Abbott’s Ensite Precision mapping system to produce those images.
"Cardiac ablation has become a front-line therapy in the fight against conditions like atrial fibrillation in part because of improvements to the technology available today," Roger Winkle, MD, an electrophysiologist at Sequoia Hospital in Redwood City, California, and one of the first physicians to treat patients with the newly approved catheter, said in the release.
"The Abbott TactiCath SE ablation catheter represents one of those major improvements, and offers an incredibly powerful, yet easy to use, combination of advanced technologies to improve ablation procedures."
The news comes several months after the FDA approved the Advisor HD Grid Mapping Catheter, another Abbott product for cardiac ablation.
Daniel joined TriMed’s Chicago editorial team in 2017 as a Cardiovascular Business writer. He previously worked as a writer for daily newspapers in North Dakota and Indiana.